HUP0301179A2 - Módosított VIII-as faktor - Google Patents

Módosított VIII-as faktor

Info

Publication number
HUP0301179A2
HUP0301179A2 HU0301179A HUP0301179A HUP0301179A2 HU P0301179 A2 HUP0301179 A2 HU P0301179A2 HU 0301179 A HU0301179 A HU 0301179A HU P0301179 A HUP0301179 A HU P0301179A HU P0301179 A2 HUP0301179 A2 HU P0301179A2
Authority
HU
Hungary
Prior art keywords
factor viii
modified factor
amino acid
hemophiliacs
loci
Prior art date
Application number
HU0301179A
Other languages
English (en)
Inventor
John S. Lollar
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of HUP0301179A2 publication Critical patent/HUP0301179A2/hu
Publication of HUP0301179A3 publication Critical patent/HUP0301179A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Abstract

A humán VIII-as faktor specifikus aminosav lókuszai kölcsönhatásbalépnek hemofíliás betegek gátló ellenanyagaival, a VIII-as faktorralvaló kezelés után. A találmány tárgyát módosított VIII-as faktorképezi, amiben az aminosav szekvencia a specifikus lókuszok közülegyben vagy több-ben meg van változtatva. A módosított VIII-as faktorjól használható hemofíliás betegek kezelésére, elkerülve vagymegakadályozva a gátló ellenanyagok hatását. Ó
HU0301179A 2000-09-19 2001-09-19 Modified factor viii HUP0301179A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23404700P 2000-09-19 2000-09-19
US23646000P 2000-09-29 2000-09-29
PCT/US2001/029431 WO2002024723A1 (en) 2000-09-19 2001-09-19 Modified factor viii

Publications (2)

Publication Number Publication Date
HUP0301179A2 true HUP0301179A2 (hu) 2003-10-28
HUP0301179A3 HUP0301179A3 (en) 2006-11-28

Family

ID=26927505

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301179A HUP0301179A3 (en) 2000-09-19 2001-09-19 Modified factor viii

Country Status (12)

Country Link
US (1) US6770744B2 (hu)
EP (1) EP1319016A4 (hu)
JP (1) JP2004525608A (hu)
KR (1) KR100638184B1 (hu)
CN (1) CN1205221C (hu)
AU (1) AU2001292861A1 (hu)
CA (1) CA2422902A1 (hu)
HU (1) HUP0301179A3 (hu)
MX (1) MXPA03002256A (hu)
PL (1) PL206105B1 (hu)
RU (1) RU2003107100A (hu)
WO (1) WO2002024723A1 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
PL2371856T3 (pl) 2004-11-12 2022-08-22 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
RU2531493C2 (ru) 2007-11-01 2014-10-20 Юниверсити Оф Рочестер Рекомбинантный фактор viii, обладающий повышенной стабильностью
KR20110022604A (ko) * 2008-05-16 2011-03-07 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
EP2498803A4 (en) * 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII IMMUNOGENICITY T LYMPHOCYTE T EPOXY VARIANTS
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
HUE046848T2 (hu) 2012-02-15 2020-03-30 Bioverativ Therapeutics Inc VIII. faktor készítmények és eljárások elõállításukra és alkalmazásukra
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
EP3001836B1 (en) 2013-05-10 2019-08-07 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
RS61305B1 (sr) 2013-06-24 2021-02-26 Xiao Weidong Preparati i metode mutantskog faktora viii
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
EP3810647A4 (en) * 2018-04-26 2022-08-17 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMOPHILIA
EP4314041A1 (en) 2021-03-30 2024-02-07 Aavnergene Inc. Modified plasma clotting factor viii and method of use thereof
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
CN113970279B (zh) * 2021-10-26 2023-07-07 珠海城市职业技术学院 数字式螺旋测微仪
CN114196677A (zh) * 2021-12-30 2022-03-18 广西医科大学第一附属医院 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
CA2225189C (en) * 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
ES2254403T3 (es) * 2000-03-22 2006-06-16 Octagene Gmbh Produccion de muteinas recombinantes de factor de coagulacion sanguinea viii en lineas de celulas humanas.

Also Published As

Publication number Publication date
EP1319016A1 (en) 2003-06-18
CN1474830A (zh) 2004-02-11
KR20030033074A (ko) 2003-04-26
HUP0301179A3 (en) 2006-11-28
EP1319016A4 (en) 2006-05-10
RU2003107100A (ru) 2004-08-27
WO2002024723A1 (en) 2002-03-28
PL206105B1 (pl) 2010-07-30
WO2002024723A9 (en) 2003-04-03
US20020182670A1 (en) 2002-12-05
AU2001292861A1 (en) 2002-04-02
PL366199A1 (en) 2005-01-24
JP2004525608A (ja) 2004-08-26
US6770744B2 (en) 2004-08-03
CA2422902A1 (en) 2002-03-28
CN1205221C (zh) 2005-06-08
KR100638184B1 (ko) 2006-10-26
MXPA03002256A (es) 2003-09-10

Similar Documents

Publication Publication Date Title
HUP0301179A2 (hu) Módosított VIII-as faktor
NL300808I2 (nl) susoctocog alfa
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE60019122D1 (de) Veränderter faktor viii
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60018591D1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE60017136D1 (de) Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat
DE602004012759D1 (de) Behandlung von fibrosen
ATE441461T1 (de) Mittel zur behandlung von infektionen
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
ATE526954T1 (de) Atomoxetin zur behandlung von allergischer rhinitis und asthma
DE602004027127D1 (de) Behandlung von aspergillus-infektionen mit thymosin alpha 1
TR200301800A2 (tr) Bir farmasötik terkip.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished